

Olpasiran sodium

Cat. No.:	HY-153492A
Molecular Formula:	$C_{490}H_{610}F_{11}N_{164}Na_{42}O_{306}P_{41}S_7$
Molecular Weight:	16361.91
Target:	Small Interfering RNA (siRNA)
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Olpasiran (sodium)

BIOLOGICAL ACTIVITY

Description

Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.

REFERENCES

[1]. Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. *Clin Ther.* 2022;44(9):1237-1247.

[2]. O'Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE). *Am Heart J.* 2022;251:61-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA